aTyr Pharma Announces Positive Phase 1 Data for ATYR1923 Therapeutic Candidate
June 26, 2018 08:00 ET
|
aTyr Pharma, Inc.
ATYR1923 Well-Tolerated at all Doses Tested, with No Significant Adverse Events Pharmacokinetic Profile Supports Potential Once-Monthly Dosing SAN DIEGO, June 26, 2018 (GLOBE NEWSWIRE) -- aTyr...
aTyr Pharma Presents Poster on Preclinical Data from ATYR1923 Program at American Thoracic Society 2018 International Conference
May 17, 2018 07:30 ET
|
aTyr Pharma, Inc.
SAN DIEGO, May 17, 2018 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological...
aTyr Pharma Doses First Subjects in Phase 1 Trial of iMod.Fc (ATYR1923)
November 27, 2017 08:00 ET
|
aTyr Pharma, Inc.
– Second Physiocrine-based therapeutic candidate enters the clinic – – Top-line data expected in 2Q 2018 – – iMod.Fc (ATYR1923) to target interstitial lung diseases with an immune component – SAN...
aTyr Pharma Announces Third Quarter 2017 Operating Results and Provides Corporate Update
November 14, 2017 16:05 ET
|
aTyr Pharma, Inc.
- Initiation of Phase 1 clinical trial of iMod.Fc on-track for this quarter - - Selection of antibody for ORCA program on-track for this quarter - SAN DIEGO, Nov. 14, 2017 (GLOBE NEWSWIRE) -- aTyr...
University of Colorado Hospital Announces new Center for Lungs and Breathing
October 01, 2015 09:05 ET
|
UCHealth
AURORA, COLO., Oct. 1, 2015 (GLOBE NEWSWIRE) -- UCHealth's University of Colorado Hospital (UCH), a national leader in pulmonology, cancer and upper airway disorders, opens its new multidisciplinary...